source,title,abstract,journal,publication_date,doi,url
PubMed,[Not Available].,,Revue de l'infirmiere,2025,10.1016/j.revinf.2024.12.017,https://pubmed.ncbi.nlm.nih.gov/39922619/
PubMed,[Difelikefalin and treatment of severe pruritus associated with chronic kidney disease Real-life retrospective study in a dialysis center].,"Difelikefalin is to date the first and only specific treatment to be approved for the treatment of moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) in adult patients on hemodialysis. This was a retrospective, single-center, real-life study in hemodialysis patients with CKD-aP treated with difelikefalin. The primary objective was to evaluate the evolution of the intensity of pruritus during treatment with difelikefalin using the Worst Itch Intensity-Numerical Rating Scale (WI-NRS). Adult patients were included if they had been on hemodialysis for at least 3 months and were suffering from moderate to severe CKD-aP (objectified by the WI-NRS score) for which difelikefalin had been prescribed. 11 patients (7 men and 4 women; mean age, 63.8 years) with a mean (SD) weekly dialysis time of 13 h (2.4) were included. The mean hemodialysis duration was 5 (3.6) years and the mean pruritus duration was 4.3 (3.2) years. At inclusion, on-going treatments of CKD-aP were emollients in all patients and antihistamines in 9 patients. The mean WI-NRS score was 7.4 (1.1) at initiation of difelikefalin. At last assessment after a median follow-up of 9.0 months, the mean change of WI-NRS score was -5.1 (2.9) and 82% of patients had a decrease ≥ 3 points. Mild to moderate adverse reactions to difelikefalin were reported in 4 patients, all of whom recovered without sequelae. These results show that difelikefalin, prescribed according to its therapeutic indication, is effective in the treatment of CKD-aP under real-life conditions, outside the controlled conditions of a clinical trial. La difélikéfaline est à ce jour le premier et le seul traitement spécifique approuvé pour le traitement du prurit d’intensité modérée à sévère associé à la maladie rénale chronique (Pa-MRC) chez les patients adultes hémodialysés. Il s’agit d’une étude rétrospective, monocentrique, en vie réelle, chez des patients hémodialysés souffrant de Pa-MRC et traités par difélikéfaline. L’objectif principal était d’évaluer l’évolution de l’intensité du prurit au cours du suivi à l’aide de l’échelle WI-NRS (Worst Itch Intensity-Numerical Rating Scale). Les patients adultes ont été inclus s’ils étaient hémodialysés depuis au moins trois mois et souffraient d’un Pa-MRC modéré à sévère (objectivé par le score WI-NRS) pour lequel la difélikéfaline avait été prescrite. Onze patients (7 hommes et 4 femmes ; âge moyen : 63,8 ans) avec un temps de dialyse hebdomadaire moyen (SD) de 13 heures (2,4) ont été inclus. La durée moyenne d’hémodialyse était de 5 ans (3,6) et la durée moyenne de prurit de 4,3 ans (3,2). À l’inclusion, les traitements du prurit en cours étaient des émollients pour tous les patients et des antihistaminiques pour 9 d’entre eux. Le score WI-NRS moyen était de 7,4 (1,1) au début du traitement par la difélikéfaline. À la dernière évaluation, après un suivi médian de 9 mois, la variation moyenne du score WI-NRS était de -5,1 (2,9) et 82 % des patients avaient une diminution ≥ 3 points. Des effets indésirables d’intensité légère à modérée liés à la difélikéfaline ont été rapportés chez 4 patients, tous rétablis sans séquelles. Ces résultats montrent que la difélikéfaline, prescrite conformément à son indication thérapeutique, est efficace en vie réelle dans le traitement du Pa-MRC, en dehors des conditions contrôlées d’un essai clinique.",Nephrologie & therapeutique,2024,10.1684/ndt.2024.78,https://pubmed.ncbi.nlm.nih.gov/39917796/
PubMed,[Patient with type 2 diabetes and progressive chronic kidney disease].,"Chronic kidney disease (CKD) is a common and severe complication in patients with type 2 diabetes (T2D). While inhibitors of the renin-angiotensin system remained for a long time the only medications that had proven nephroprotective effects, several other pharmacological classes also recently showed such a benefit : sodium-glucose cotransporter type 2 (SGLT2) inhibitors (gliflozins), glucagon-like peptide-1 receptor agonists (semaglutide), and mineralocorticoid receptor antagonists (MRA, finerenone). This clinical vignette aims at explaining the pharmacotherapy strategy for a patient with T2D who presents a progressive CKD. The interest of prescribing a combination of several medications with complementary actions that had proven a nephroprotection is emphasized. La maladie rénale chronique (MRC) représente une complication fréquente et grave affectant les patients vivant avec un diabète de type 2 (DT2). Alors que les inhibiteurs du système rénine-angiotensine sont restés longtemps les seuls médicaments à avoir démontré une néphroprotection indiscutable, plusieurs autres classes pharmacologiques ont récemment prouvé un tel bénéfice : les inhibiteurs des cotransporteurs sodium-glucose de type 2 (iSGLT2 ou gliflozines), les agonistes des récepteurs du glucagon-like peptide-1 (sémaglutide) et les antagonistes des récepteurs aux minéralocorticoïdes (finérénone). Cette vignette clinique a pour but d’expliquer le cheminement de la pharmacothérapie d’un patient avec un DT2 qui présente une MRC évolutive et d’insister sur l’intérêt d’une combinaison de médicaments néphroprotecteurs à action complémentaire.",Revue medicale de Liege,2025,,https://pubmed.ncbi.nlm.nih.gov/39815707/
PubMed,[Peritoneal dialysis in treatment of end-stage renal disease].,"PERITONEAL DIALYSIS IN THE TREATMENT OF END-STAGE RENAL DISEASE. Peritoneal dialysis (PD) is a replacement therapy for patients with stage 5 chronic kidney disease (CKD5). Its use varies from country to country. In France, only 11% of CKD5 patients are treated with PD, with great disparity between regions, the majority being supported with center hemodialysis (HD). Yet this treatment offers many advantages. It is a home-based treatment, allowing greater autonomy, and easy for patients to learn. In the event of incapacity, assistance can be provided by a nurse or a relative. No vascular approach is required. Its effectiveness in terms of patient survival is at least identical to that of HD patients. It is vital that all patients at MRC4 or 5 stage should be managed within the care pathway recommended by Haute Autorité de santé, so that they can benefit, among other things, from informed pre-dialysis information on the different dialysis modalities. DIALYSE PÉRITONÉALE DANS LE TRAITEMENT DE LA MALADIE RÉNALE CHRONIQUE TERMINALE. La dialyse péritonéale (DP) est un traitement de suppléance des patients atteints de maladie rénale chronique de stade 5 (MRC5). Son utilisation est variable d’un pays à l’autre. En France, seulement 11 % des patients atteints de MRC5 sont traités par DP avec une grande disparité interrégionale, la majorité étant prise en charge en centre d’hémodialyse (HD). Pourtant, la DP offre de nombreux avantages. C’est un traitement à domicile permettant ainsi plus d’autonomie et facile à apprendre par le patient. En cas d’incapacité, une assistance par une infirmière ou un proche peut être mise en place. Il n’y a pas de nécessité de voie d’abord vasculaire. Son efficacité en matière de survie des patients est au moins identique à celle des patients en HD. Il est capital que tous les patients au stade de MRC 4 ou 5 soient pris en charge dans le parcours de soins recommandé par la Haute Autorité de santé afin de bénéficier entre autres d’une information pré-dialyse éclairée sur les différentes techniques existantes.",La Revue du praticien,2024,,https://pubmed.ncbi.nlm.nih.gov/39625014/
PubMed,[Association between iron deficiency and risk of major events in chronic kidney disease].,"Iron deficiency (ID) is common in patients with chronic kidney disease (CKD) but remains under-diagnosed and its prognosis poorly documented in the absence of anemia. The aim of the study was to assess the relationship between ID and the risk of major adverse outcomes in patients with CKD. Using data from the French Chronic Kidney Disease - Renal Epidemiology and Information Network (CKD-REIN) cohort which included and followed over five years, 3,033 patients with CKD stages 2 to 5 CKD, we estimated the prevalence of ID, defined by a ferritin level < 100 μg/L and/or a transferrin saturation < 20%, and associated hazard ratios (HR) of kidney failure with replacement therapy, kidney failure defined by an eGFR < 15 mL/min per 1.73 m2 or initiation of kidney replacement therapy, all-cause mortality, and death or hospitalization for heart failure. Baseline prevalence of ID in the cohort (66% men; mean age 67 ± 13 years) was 50% (48-52). Mean hemoglobin was 13 ± 1.7 g/dL, and only 31% of patients with ID also had a hemoglobin < 12 g/dL. In 2,803 patients with CKD stages 2-4 at baseline, ID was associated with significant increased risk of kidney failure, and of kidney failure with replacement therapy, with HRs adjusted for confounders and hemoglobin level of 1.22 (1.03-1.45) and 1.57 (1.27-1.94), respectively. Adjusted HRs for all-cause mortality and hospitalization or death for heart failure, were 1.31 (1.04-1.66) and 1.38 (1.07-1.80), respectively. This study shows that ID is significantly associated with the risk for kidney failure, all-cause mortality, and heart failure, independent of the presence of anemia. La carence martiale (CM) est fréquente chez les patients atteints de maladie rénale chronique (MRC), mais reste sous-diagnostiquée et son pronostic mal documenté en l’absence d’anémie. L’étude visait à évaluer la relation entre la CM et le risque d’événements majeurs chez les patients atteints de MRC. Dans la cohorte française Chronic Kidney Disease – Renal Epidemiology and Information Network (CKD-REIN), qui a inclus et suivi pendant cinq ans 3 033 patients atteints de MRC de stades 2 à 5, nous avons estimé la prévalence de la CM, définie par un taux de ferritinémie < 100 μg/L et/ou un coefficient de saturation de la transferrine < 20 %, et les hazard ratios (HR) associés de défaillance rénale avec traitement de suppléance, de défaillance rénale définie par un eGFR < 15 mL/min pour 1,73 m2 ou l’initiation d’un traitement de suppléance, de mortalité et d’insuffisance cardiaque. La prévalence de la CM à l’inclusion dans la cohorte (66 % d’hommes ; âge moyen 67 ± 13 ans) était de 50 % (48-52). Le taux moyen d’hémoglobine était de 13 ± 1,7 g/dL et seuls 31 % des patients avec une CM avaient une hémoglobine < 12 g/dL. Chez les 2 803 patients avec une MRC stades 2-4 à l’inclusion, la CM était associée à une augmentation significative du risque de défaillance rénale et de défaillance rénale avec traitement de suppléance, avec des HR ajustés sur les facteurs de confusion et le taux d’hémoglobine respectivement de 1,22 (1,03-1,45) et 1,57 (1,27-1,94). Les HR ajustés de mortalité toutes causes, et d’hospitalisation ou de décès pour une insuffisance cardiaque liés à la CM étaient respectivement de 1,31 (1,04-1,66), et 1,38 (1,07-1,80). Cette étude montre que la CM est associée au risque de défaillance rénale, de mortalité et d’insuffisance cardiaque indépendamment de la présence, ou non, d’une anémie.",Nephrologie & therapeutique,2024,10.1684/ndt.2024.91,https://pubmed.ncbi.nlm.nih.gov/39559991/
PubMed,[Uremic pericarditis in a not-so-terminal chronic kidney disease].,"A 90-year-old patient with chronic kidney disease (stage G4) was diagnosed with pneumonia and congestive heart failure. Despite treatment with levofloxacin and furosemide, his condition deteriorated. A CT scan of the chest revealed pericardial effusion, leading to the suspicion of uremic pericarditis. Daily hemodialysis was started, resulting in significant clinical and biological improvement. Uremic pericarditis due to accumulation of uremic toxins resulting in pericardial effusion is common in end-stage renal disease. Diagnosis is guided by clinical and paraclinical findings and a high index of suspicion. Early recognition and treatment remain critical to prevent complications even in pre-end stage renal disease.",Revue medicale suisse,2024,10.53738/REVMED.2024.20.894.2081,https://pubmed.ncbi.nlm.nih.gov/39506481/
PubMed,[Not Available].,,Revue medicale suisse,2024,10.53738/REVMED.2024.20.891.1907,https://pubmed.ncbi.nlm.nih.gov/39429190/
PubMed,[Management of chronic kidney disease in primary care: New practical guidelines in primary care].,"Chronic kidney disease is often encountered in clinical practice, affecting between 8 and 16% of the world's population. Screening for CKD represents a major challenge for patients, given the increase in morbidity and mortality associated with the disease, as well as a public health issue in terms of slowing the progression to end-stage renal failure, which requires costly replacement treatments (dialysis and transplantation). The new KDIGO guidelines suggest aiming for optimal control of the cardiovascular risk factors associated with chronic kidney disease, in particular with the help of emerging treatments such as SGLT2 inhibitors. This article summarises the latest nephroprotection recommendations for primary care physicians. La maladie rénale chronique est fréquemment rencontrée en pratique clinique et touche 8 à 16 % de la population mondiale. Son dépistage représente un enjeu considérable pour les patients du fait de l’augmentation de la morbidité et de la mortalité qui y sont liées, ainsi qu’un enjeu de santé publique dans le ralentis­sement de la progression vers l’insuffisance rénale terminale nécessitant des traitements substitutifs coûteux (dialyse, transplantation). Les nouvelles guidelines KDIGO proposent de viser un contrôle optimal des facteurs de risque cardiovasculaire associés à la maladie rénale chronique, notamment à l’aide de traitements émergents tels que les inhibiteurs du SGLT2. Cet article propose une synthèse des dernières recommandations dans la néphroprotection à l’intention des médecins de premier recours.",Revue medicale suisse,2024,10.53738/REVMED.2024.20.888.1687,https://pubmed.ncbi.nlm.nih.gov/39323269/
PubMed,Screening and Diagnosis of Chronic Kidney Disease in Adults Living With Diabetes: A Retrospective Cohort Study Using the Canadian Primary Care Sentinel Surveillance Network.,"In Canada, regional evaluations of screening practices for chronic kidney disease (CKD) among people with diabetes highlight areas for improvement; however, national estimates are notably absent. Estimates of CKD incidence often discount the expected decline in estimated glomerular filtration rate (eGFR) associated with age; age-adaptive thresholds may help account for this. We describe the frequency of screening and diagnosis of CKD among adults with diabetes from a nationally representative primary care cohort. In this retrospective cohort study, we used electronic medical record data from the Canadian Primary Care Sentinel Surveillance Network. We followed adult patients (≥18 years of age) with diabetes without CKD at baseline for 5 years starting in 2014. We determined the frequency of urine albumin-to-creatinine ratio (uACr) and/or eGFR testing over time. We identified incident CKD diagnoses based on eGFR measurements using fixed-threshold and age-adaptive definitions and quantified the incidence proportion and rate. We analyzed records from 37,604 patients with diabetes. Only 13% of patients had yearly eGFR and uACr testing for CKD, although roughly 60% had non-yearly use of both tests in 5 years. eGFR testing was performed more frequently than uACr testing (94.1% vs 76.6% having testing over follow-up). We found increased incidence proportions (14.6% vs 6.0%) and rates (33.1 vs 13.4 diagnoses per 1,000 person-years) of CKD using the fixed-threshold compared with age-adaptive definition. Our study presents the first national understanding of screening practices for CKD among people with diabetes in Canada. Specifically, increased use of uACr testing should be encouraged for early detection of changes in kidney function.",Canadian journal of diabetes,2024,10.1016/j.jcjd.2024.08.001,https://pubmed.ncbi.nlm.nih.gov/39134119/
PubMed,[Characteristics and needs of patients requiring nephrology care: A review of the literature].,"Chronic kidney disease (CKD) is a public health problem. However, the management of patients with CKD is confined to the diagnosis of the disease and its conventional treatment by dialysis or renal transplantation. The aim of this article is to describe the specific characteristics of patients suffering from kidney disease and to determine their needs according to the stage of their renal disease.",Soins; la revue de reference infirmiere,2024,10.1016/j.soin.2024.05.006,https://pubmed.ncbi.nlm.nih.gov/39019509/
PubMed,[Detection and diagnosis of chronic kidney disease to take action as early as stage 3].,"DETECTION AND DIAGNOSIS OF CHRONIC KIDNEY DISEASE TO TAKE ACTION AS EARLY AS STAGE 3. The prevalence of chronic kidney disease (CKD) is constantly increasing. The considerable impact of CKD on all-cause mortality, cardiovascular morbidity and on health economy makes it a real public health issue. Early detection helps to prevent progression to advanced stages of the disease. Targeted screening in populations at risk is recommended, with the use of 3 tests: serum creatinine, estimation of GFR and measurement of albumin/creatinine ratios. Once diagnosed, management of CKD involves nephroprotective measures such as blood pressure management, correction of metabolic complications, and prevention of drug toxicity. The general practitioner has a central role in the screening and initial management of CKD. DÉPISTAGE ET DIAGNOSTIC DE LA MALADIE RÉNALE CHRONIQUE POUR AGIR DÈS LE STADE 3. La prévalence de la maladie rénale chronique (MRC) est en constante augmentation. L’impact considérable de la MRC sur la mortalité toutes causes, sur la morbidité cardiovasculaire et sur l’économie de la santé en fait un véritable enjeu de santé publique. Le dépistage précoce permet de prévenir la progression vers des stades avancés de la maladie. Le dépistage ciblé chez les populations à risque est recommandé, avec l’utilisation de trois tests : créatininémie, estimation du débit de filtration glomérulaire (DFG) et mesure du rapport albumine/créatinine (RAC). Une fois diagnostiquée, la prise en charge de la MRC implique des mesures de néphroprotection telles que la gestion de la pression artérielle, la correction des complications métaboliques et la limitation de la toxicité médicamenteuse. Le médecin généraliste joue un rôle central dans le dépistage et la prise en charge initiale de la MRC.",La Revue du praticien,2024,,https://pubmed.ncbi.nlm.nih.gov/39011716/
PubMed,[Chronic kidney disease: how to benefit form coordinated care?].,"HOW TO BENEFIT FORM COORDINATED CARE? Chronic kidney disease (CKD) is a major goal of public health. At each stage of CKD, from screening to renal replacement therapy, coordinated care at geographic level or population-based may contribute to enhance effectiveness and efficiency. Kidney transplantation, home-dialysis and conservative treatment must be prioritized. MALADIE RÉNALE CHRONIQUE : BIEN CONNAÎTRE LE PARCOURS DE SOINS SUR SON TERRITOIRE. Du point de vue du système de soins, la maladie rénale chronique (MRC) est un modèle de maladie chronique. Aux différents stades de l’évolution de la MRC, du dépistage à la suppléance, une coordination du parcours sur chaque territoire et une approche populationnelle des différents acteurs – MSP, CPTS, structures hospitalières... – contribuent à l’efficacité et l’efficience des soins. L’éducation thérapeutique est centrale pour permettre au patient d’être assuré, rassuré, en gagnant en autonomie. La greffe, la dialyse autonome et le traitement conservateur sont prioritaires.",La Revue du praticien,2024,,https://pubmed.ncbi.nlm.nih.gov/39011715/
PubMed,[Chronic kidney disease : a genuine public health burden].,"A GENUINE PUBLIC HEALTH BURDEN. Chronic kidney disease (CKD) is a frequent pathology. It requires regular screening and, once diagnosed, specific follow-up. Complications are serious, as end-stage CKD needs renal replacement therapy, and cardiovascular events are common. Over and above its complications, CKD also impacts the quality of life of patients. ""LA MALADIE RÉNALE CHRONIQUE : UN AUTHENTIQUE FARDEAU DE SANTÉ PUBLIQUE. La maladie rénale chronique (MRC) est une pathologie fréquente. Il est nécessaire de la dépister régulièrement, puis de mettre en place un suivi spécifique lorsqu’elle est diagnostiquée. Ses complications sont graves, car à un stade dit terminal, la MRC nécessite un traitement de suppléance rénale, et les événements cardiovasculaires sont fréquents. Au-delà des complications cliniques, la MRC impacte également la qualité de vie des patients.""",La Revue du praticien,2024,,https://pubmed.ncbi.nlm.nih.gov/39011714/
PubMed,[Role of the general practitioner in enhancing the management of chronic kidney disease].,,La Revue du praticien,2024,,https://pubmed.ncbi.nlm.nih.gov/39011712/
PubMed,[Prevalence of stages 3-5 chronic kidney disease in New Caledonia].,"New Caledonia is a French territory located in the South Pacific Ocean. The prevalence rate of end-stage renal disease is nearly 3,000 per million inhabitants, making it one of the highest prevalence rates in the world. Preventing chronic kidney disease is a major public health issue. This article presents prevalence rates of chronic kidney disease (CKD) stages 3-5 for New Caledonia defined by a glomerular filtration rate estimated below 60 mL/min/1.73 m2. Estimation was assessed from data collected during two “Adult health barometer” surveys carried out in the general adult population. Therefore, our study assessed two prevalence rates: 7.8% [6.1; 10.1] and 5.3% [3.3; 8.5]. Those prevalence rates were two to four times higher than in mainland France which is consistent with the high prevalence rate of end stage renal disease treated in New Caledonia. Hence, CKD prevention is essential for New Caledonia. La Nouvelle-Calédonie est une collectivité française dans l’océan Pacifique Sud. Le taux de prévalence de l’insuffisance rénale chronique terminale traitée s’élève à près de 3 000 par million d’habitants, soit un des taux de prévalence parmi les plus élevés au monde. Cet article présente pour la première fois les taux de prévalence de la maladie rénale chronique aux stades 3-5 pour la Nouvelle-Calédonie, définie par un débit de filtration glomérulaire estimé inférieur à 60 mL/min/1,73 m2. Ces résultats ont été estimés à partir des deux enquêtes « Baromètre santé adulte » en population générale adulte. Notre étude a estimé des taux de prévalence de 7,8 % [6,1 ; 10,1] et de 5,3 % [3,3 ; 8,5]. Le taux de prévalence de la maladie rénale chronique serait donc deux à quatre fois plus élevé qu’en France métropolitaine. La prévention de la maladie rénale chronique est primordiale pour la Nouvelle-Calédonie.",Nephrologie & therapeutique,2024,10.1684/ndt.2024.77,https://pubmed.ncbi.nlm.nih.gov/38920046/
PubMed,[Non-pharmacological prevention of chronic kidney disease].,"Preventing chronic kidney disease (CKD) is a major public health objective. CKD leads to significant cardiovascular morbidity and mortality, with a negative impact on quality of life and significant societal repercussions. Several drugs are effective in preventing and curbing CKD, including blockers of the renin/angiotensin/aldosterone system and inhibitors of the SGLT2 co-transporter. New molecules are currently in clinical trials focusing on the nephro-protection, such as non-steroidal mineralocorticoid receptor antagonists and GPL-1 receptor agonists. In addition to this drug arsenal, CKD prevention also relies on non-pharmacological optimization of hygienic-dietary measures, including smoking avoidance, physical activity and dietetics. The aim of this article is to detail this non-medicinal approach to the prevention and slow down of CKD. La prévention de la maladie rénale chronique (MRC) est un objectif majeur de santé publique. La MRC engendre, en effet, une morbi-mortalité cardiovasculaire importante, avec un impact négatif sur la qualité de vie et des répercussions sociétales non négligeables. Plusieurs piliers médicamenteux sont efficaces dans la prévention et la freination de la MRC, tels que les bloqueurs du système rénine/angiotensine/aldostérone et les inhibiteurs du co-transporteur SGLT2. De nouvelles molécules sont en cours d’essais cliniques visant la néphro-protection, comme les antagonistes non stéroïdiens du récepteur aux minéralocorticoïdes et les agonistes du récepteur au GPL-1. Outre cet arsenal médicamenteux, la prévention de la MRC repose également sur une optimisation non pharmacologique des mesures hygiéno-diététiques, comprenant l’éviction tabagique, l’activité physique et la diététique. L’objectif de cet article est de détailler cette approche non médicamenteuse dans la prévention et la freination de la MRC.",Revue medicale de Liege,2024,,https://pubmed.ncbi.nlm.nih.gov/38869132/
PubMed,[Why is health literacy an essential component of health of individuals with chronic kidney disease].,"Health literacy (HL) is the ability of individuals to access, understand and use health information to improve their health. It is a multidimensional and contextual concept, whose definition has been enriched over time. Considered both as a health risk factor and a skill to be developed by individuals, HL also depends on the healthcare system in which patients have to navigate, and on healthcare professionals’ awareness of this concept. In order to promote shared decision-making and thus individual empowerment in the healthcare, HL should be at the core of the concerns of nephrology care teams. La littératie en santé (LS) est la capacité d’un individu à accéder à des informations en santé, à les comprendre et à les utiliser pour améliorer son état de santé. Il s’agit d’un concept pluridimensionnel et contextuel dont la définition s’est enrichie au fil du temps. Considérée à la fois comme un facteur de risque pour la santé et une aptitude à développer chez les individus, la LS dépend également du système de santé dans lequel les patients doivent naviguer et de la sensibilisation des professionnels de santé à ce concept. Afin de favoriser la décision partagée et ainsi l’émancipation des individus en matière de santé, la LS devrait être au cœur des préoccupations des équipes de néphrologie.",Nephrologie & therapeutique,2024,10.1684/ndt.2024.71,https://pubmed.ncbi.nlm.nih.gov/38742302/
PubMed,[Chronic kidney disease in geriatrics].,"Chronic kidney disease (CKD) affects almost 10% of the world's population, and over 30% of people aged over 70 [1,2]. The overall incidence of treated CKD is stable in France, but continues to rise sharply in people aged over 85 [3]. In its advanced stages, CKD is associated with numerous complications linked to disturbances in water, acid-base and phosphocalcium balance, as well as anemia and increased cardiovascular risk. A better understanding of risk factors, improved practices to promote nephroprotection, and progress in therapeutic education and preparation for suppletive techniques would help reduce this risk.",Soins. Gerontologie,2024,10.1016/j.sger.2024.01.003,https://pubmed.ncbi.nlm.nih.gov/38418074/
PubMed,[Neurocognitive disorders in chronic kidney disease].,"Neurocognitive disorders (NCD) are common in patients with chronic kidney disease (CKD). It is essential to identify and characterize these disorders at an early stage, so as to be able to offer appropriate treatment. In a chronic disease such as CKD, the patient's involvement in decision-making is a major challenge, given the prospects for suppletive treatment: hemodialysis, peritoneal dialysis, kidney transplantation or non-dialytic drug therapy. Many factors are associated with the development and progression of NCD in patients with CKD, and a variety of conditions can influence the outcome of cognitive assessment in these patients.",Soins. Gerontologie,2024,10.1016/j.sger.2024.01.005,https://pubmed.ncbi.nlm.nih.gov/38418068/
PubMed,"[Substitution treatments for chronic kidney disease in geriatrics: dialysis, transplantation and medical treatment without dialysis].","Kidney disease, whether acute or chronic, is a particularly common condition in the elderly, due to its main risk factors, the prevalence of which increases with age, and the fact that recovery from acute tubular damage is slower. Wherever possible, treatment of renal failure should be anticipated and discussed with the patient as part of a shared medical decision. Numerous treatment options are available to ensure maximum integration into the patient's life and care plan: renal transplantation for the most robust patients, hemodialysis in a care facility or at home, peritoneal dialysis at home, or medical treatment without dialysis. The choice of one of these treatments must leave the patient free to change his or her treatment modality at any time.",Soins. Gerontologie,2024,10.1016/j.sger.2024.01.004,https://pubmed.ncbi.nlm.nih.gov/38418067/
PubMed,Haematological Indices and Iron Status in Pre-Dialysis Chronic Kidney Disease Patients.,"Chronic kidney disease (CKD) is associated with haematological changes, the commonest being anaemia. The number and function of white blood cells (WBC) and platelets are equally affected. Iron deficiency is a common cause of anaemia in the CKD population and anaemia has been associated with reduced cardiac function, increased rates of hospitalization, morbidity and mortality. This study aimed to determine the haematological indices and iron status among pre-dialysis CKD patients. A hospital-based cross-sectional study involving 95 predialysis CKD patients and 95 age- and sex-matched apparently healthy controls. Full blood count, peripheral blood film, serum ferritin, transferrin saturation, C-reactive protein (CRP), electrolytes, urea and creatinine, serum folate and vitamin B12 were done in all study participants. Comparisons were made between results obtained from participants in both groups. The mean ages were 58.1 ± 14.9 years and 58.3 ± 15.0 years in the CKD group and controls, respectively. The male:female ratio was 1:0.9 in both groups. The prevalence of anaemia was 51.6% and 3% in patients with CKD and controls, respectively. There was no significant difference in the total WBC count, neutrophil and lymphocyte differentials, platelet count, serum vitamin B12 and folate in patients with CKD and controls. The prevalence of iron deficiency among patients with CKD was 32.6%, of which 62.5% were absolutely iron-deficient while 37.5% were functionally iron-deficient. The median ferritin and CRP were also higher in CKD. (p =0.001). Anaemia and iron deficiency are common in predialysis CKD patients. Early diagnosis and treatment are important to avoid the problems associated with them. Maladie rénale chronique, Anémie, Carence en fer, Pré-dialyse.",West African journal of medicine,2024,,https://pubmed.ncbi.nlm.nih.gov/38412204/
PubMed,[Diagnosis and management of pruritus associated with chronic kidney disease in hemodialyzed patients].,"Chronic kidney disease-associated pruritus (CKD-aP) is a disabling symptom which is frequent and often underestimated. Pa-MRC has a negative impact on quality of life, and is frequently accompanied by sleep disorders and depression. The approval of difelikefalin – a kappa opioid receptor agonist – in this indication requires updated recommendations. As a first step, secondary causes of pruritus without skin lesions must be ruled out, and general measures taken (emollients, psychological support, optimization of dialysis, normalization of serum calcium, phosphate and PTH in the range proposed by the KGIDO guidelines, treatment of iron deficiency). A therapeutic test with a non-sedating oral antihistamine may be proposed. If this test is negative, Pa-MRC must be strongly suspected, and its intensity (WI-NRS scale) and impact on quality of life assessed. In the case of mild Pa-MRC (WI-NRS ≤ 3), only general measures are implemented. If Pa-MRC is moderate to severe (WI-NRS ≥ 4), specific treatment with difelikefaline can be initiated for 6 months in addition to general measures. At 3 months, if the response is complete (WI-NRS score ≤ 1) or partial (decline ≥ 3 points), treatment is continued. At 6 months, if the response is complete, treatment may be discontinued with the patient’s agreement; treatment is maintained if the response is partial. At 3 or 6 months, if response is insufficient (decline < 3 points) and/or in the event of intolerance, treatment is discontinued and an alternative treatment (e.g., gabapentinoids, UVB) may be considered after dermatological consultation. Le prurit associé à la maladie rénale chronique (Pa-MRC) est un symptôme invalidant qui est fréquent et souvent sous-estimé. Le Pa-MRC a des conséquences négatives sur la qualité de vie et s’accompagne fréquemment de troubles du sommeil et de dépression. L’approbation de la difélikéfaline – agoniste des récepteurs opioïdes kappa – dans cette indication nécessite l’actualisation des recommandations. Les causes secondaires de prurit sans lésions cutanées doivent être exclues et des mesures générales doivent être prises (émollients, aide psychologique, optimisation de la dialyse, équilibre phosphocalcique avec parathormone [PTH] dans la cible KDIGO [Kidney Disease: Improving Global Outcomes], traitement de la carence martiale). Une épreuve thérapeutique avec un antihistaminique oral non sédatif peut être proposée. En cas de test négatif, il faut fortement suspecter un Pa-MRC et évaluer son intensité (échelle WI-NRS [Worst Itch Numeric Rating Scale]) et son impact sur la qualité de vie. En cas de Pa-MRC léger (WI-NRS ≤ 3), seules les mesures générales sont mises en œuvre. Si le Pa-MRC est modéré à sévère (WI-NRS ≥ 4), un traitement spécifique par difélikéfaline peut être instauré pour 6 mois en plus des mesures générales. À 3 mois, si la réponse est complète (score WI-NRS ≤ 1) ou partielle (baisse ≥ 3 points), le traitement est poursuivi. À 6 mois, si la réponse est complète, l’arrêt du traitement peut être envisagé avec l’accord du patient ; il est maintenu en cas de réponse partielle. À 3 ou 6 mois, en cas de réponse insuffisante (baisse < 3 points) et/ou d’intolérance, le traitement est interrompu et un autre traitement (par exemple, gabapentinoïdes, ultraviolet de type B [UVB]) peut être envisagé après avis dermatologique.",Nephrologie & therapeutique,2024,10.1684/ndt.2024.60,https://pubmed.ncbi.nlm.nih.gov/38294264/
PubMed,"Pregnancy outcomes in women with primary Sjögren's syndrome: an analysis of data from the multicentre, prospective, GR2 study.","Adverse pregnancy outcomes in women with primary Sjögren's syndrome have only been evaluated retrospectively using heterogeneous methods and with contradictory results. We aimed to describe adverse pregnancy, delivery, and birth outcome risks in pregnant women with primary Sjögren's syndrome compared with those of a matched general population in France, and to identify factors predictive of disease flares or adverse pregnancy outcomes. We conducted a multicentre, prospective, cohort study in France using the GR2 (Groupe de Recherche sur la Grossesse et les Maladies Rares) registry. Women from the GR2 study were eligible if they had conceived before March, 2021, had primary Sjögren's syndrome according to the American College of Rheumatology and European Alliance of Associations for Rheumatology (EULAR) 2016 classification criteria, and had an ongoing pregnancy at 12 weeks of gestation. In women who entered in the registry with pregnancies before 18 weeks of gestation, we sought to identify factors associated with primary Sjögren's syndrome flare (≥3-point increase in EULAR Sjögren's Syndrome Disease Activity Index [ESSDAI] score) or adverse pregnancy outcomes (fetal or neonatal death, placental insufficiency leading to a preterm delivery [<37 weeks of gestation], or small-for-gestational-age birthweight). A matched controlled study compared adverse pregnancy, delivery, and birth outcome rates between pregnant women with primary Sjögren's syndrome from the GR2 registry and matched controls from the general population included in the last French perinatal survey (Enquête Nationale Périnatale 2016). 1944 pregnancies were identified in the GR2 cohort, of which 106 pregnancies in 96 women with primary Sjögren's syndrome were included in this analysis. The median age at pregnancy onset was 33 years (IQR 31-36). 87 (83%) of 105 pregnancies (with ethnicity data) were in White women, 18 (17%) were in Black women; 92 (90%) of 102 had previous systemic activity (ESSDAI score of ≥1; data missing in four pregnancies), and 48 (45%) of 106 had systemic activity at inclusion. Of 93 pregnancies included at week 18 of gestation or earlier, primary Sjögren's syndrome flares occurred in 12 (13%). No baseline parameters were associated with primary Sjögren's syndrome flare. Four twin pregnancies and one medical termination were excluded from the adverse pregnancy outcome analysis; of the remaining 88, adverse pregnancy outcomes occurred in six (7%). Among pregnancies in women with data for antiphospholipid antibodies (n=55), antiphospholipid antibody positivity was more frequent among pregnancies with adverse outcomes (two [50%] of four pregnancies) compared with those without adverse outcomes (two [4%] of 51 pregnancies; p=0·023). Anti-RNP antibody positivity was also more frequent among pregnancies with adverse outcomes than those without, although this was not statistically significant. In the matched controlled study, adverse pregnancy outcomes occurred in nine (9%) of 105 pregnancies in women with primary Sjögren's syndrome and 28 (7%) of the 420 matched control pregnancies; adverse pregnancy outcomes were not significantly associated with primary Sjögren's syndrome (odds ratio 1·31, 95% CI 0·53-2·98; p=0·52). Pregnancies in women with primary Sjögren's syndrome had very good prognoses for mothers and fetuses, with no overall increase in adverse pregnancy outcome risk compared with the general population. Women with antiphospholipid antibodies or anti-RNP antibodies require close monitoring, because these factors might be associated with a higher risk of adverse pregnancy outcomes. Lupus France, Association des Sclérodermiques de France, Association Gougerot Sjögren, Association Francophone Contre la Polychondrite Chronique Atrophiante, AFM-Telethon, Société Nationale Française de Médecine Interne, Société Française de Rhumatologie, Cochin Hospital, French Health Ministry, Fondation for Research in Rheumatology, Association Prix Véronique Roualet, Union Chimique Belge.",The Lancet. Rheumatology,2023,10.1016/S2665-9913(23)00099-1,https://pubmed.ncbi.nlm.nih.gov/38251600/
PubMed,"Chronic kidney disease in America, Africa, and Asia: Overview of treatment cost and options.","Chronic kidney disease (CKD) is one of the non-infectious diseases that threaten patients' lives on a daily basis. Its prevalence is high, but under-reported by patients and those living with the disease, as it is silent and asymptomatic in the early stages. Kidney disease increases the risk of heart and vascular disease. These problems can manifest themselves slowly, over a long period of time. Early detection and treatment can often prevent chronic kidney disease from worsening. As kidney disease progresses, it can lead to kidney failure, requiring dialysis or a kidney transplant to stay alive. In this narrative review, we will mainly discuss different treatment option costs in different countries and how much they cost healthcare systems in countries in three different continents.",Annales pharmaceutiques francaises,2024,10.1016/j.pharma.2024.01.002,https://pubmed.ncbi.nlm.nih.gov/38218427/
PubMed,"[Finerenone (Kerendia®), a new weapon against the chronic kidney disease of a patient with type 2 diabetes].","Finerenone, a new nonsteroidal mineralocorticoid receptor antagonist, showed a significant reduction in a primary composite renal outcome in FIDELIO-DKD and a significant reduction in a primary composite cardiovascular outcome in FIGARO-DKD in patients with type 2 diabetes (T2D) and a chronic kidney disease (CKD). In a subsequent analysis that combined these two clinical trials (FIDELITY), the reduction becomes statistically significant when compared to placebo for both outcomes, with a hazard ratio of 0.86 (95 % confidence interval 0.78-0.95; P = 0.0018) for the cardiovascular outcome and 0.77 (0.67-0.88; P = 0.0002) for the renal outcome. Furthermore, all renal events occurred less frequently with finerenone than with placebo, including the progression to end-stage CKD independently of the baseline levels of glomerular filtration rate and albuminuria and regardless of associated medications (including gliflozins). The safety profile was excellent. However, a significant increase in serum potassium level was observed. Even if it is less pronounced than the increase usually seen with spironolactone, the risk of hyperkalemia requires some caution regarding both patient selection and monitoring. Finerenone (Kerendia®) is indicated in the treatment of CKD with albuminuria in adult patients with T2D. In Belgium, it is reimbursed with conditions in combination with a renin-angiotensin blocker. La finérénone, un nouvel antagoniste non stéroïdien du récepteur des minéralocorticoïdes, a montré, dans deux grandes études réalisées chez des patients avec un diabète de type 2 (DT2) et une maladie rénale chronique (MRC), une réduction significative du critère composite rénal dans FIDELIO-DKD et du critère composite cardiovasculaire dans FIGARO-DKD. Dans une analyse combinant les deux études (FIDELITY), la réduction est statistiquement significative dans le groupe finérénone par rapport au groupe placebo pour les deux critères, avec un hasard ratio de 0,86 (intervalle de confiance à 95 % 0,78-0,95; P = 0,0018) pour le critère cardiovasculaire et de 0,77 (0,67-0,88; P = 0,0002) pour le critère rénal. De plus, tous les événements rénaux surviennent moins fréquemment sous finérénone que sous placebo, y compris la progression vers l’insuffisance rénale terminale et ce, indépendamment du niveau du débit de filtration glomérulaire et de l’albuminurie à l’inclusion dans les essais ou des traitements associés (y compris les gliflozines). Le profil de sécurité est excellent, avec cependant une élévation de la kaliémie. Si elle est moindre que celle observée avec la spironolactone, elle nécessite néanmoins des précautions d’usage en termes de sélection des patients et de leur surveillance. La finérénone (Kerendia®) est indiquée dans le traitement de la MRC avec albuminurie chez le patient adulte avec DT2 et est remboursée en Belgique, sous conditions, en association avec un bloqueur du système rénine-angiotensine.",Revue medicale de Liege,2023,,https://pubmed.ncbi.nlm.nih.gov/38095038/
PubMed,[Cognitive impairment and the blood-brain barrier in chronic kidney disease: role of the uremic toxins].,"Patients with chronic kidney disease (CKD) have an increased risk of cognitive disorders, presenting as vascular dementia, compared with the general population. These cognitive disorders occur early during the course of the kidney disease and evolve in parallel with the decline in glomerular filtration rate. They affect 30 to 80 % of patients with stage 5 CKD. Kidney transplantation only partially improves cognitive impairment. In this narrative review, we summarize the epidemiology and recent clinical and experimental data on cognitive impairment in CKD and discuss the potential specific mechanisms. Among the factors associated with cognitive impairment, the accumulation of uremic toxins such as indoxyl sulfate appears to be a specific risk factor for cognitive decline. These toxins have an endothelial toxicity that can disrupt the cerebral endothelium. The rupture of the blood-brain barrier (BBB) is a mechanism implicated in several neurodegenerative pathologies and systemic diseases with cerebral tropism. Recent experimental findings in CKD indicate that disruption of the BBB appears to be an important mechanism behind cognitive impairment in CKD. In murine models of CKD, increased BBB permeability is linked to memory impairment and aryl hydrocarbon receptor activation following accumulation of circulating indoxyl sulfate. This disruption of the BBB could also have harmful consequences for stroke susceptibility and drug neurotoxicity in CKD patients. Les patients atteints de maladie rénale chronique (MRC) présentent un risque accru de troubles neurocognitifs par rapport à la population générale, se présentant sous la forme d’une démence vasculaire. Ces troubles cognitifs interviennent précocement dans la maladie rénale et évoluent en parallèle au déclin du débit de filtration glomérulaire. Ils concernent 30 à 80 % des patients au stade 5 de la MRC. La transplantation rénale n’améliore que partiellement les troubles cognitifs. Dans cette revue narrative, nous résumons l’épidémiologie et les données cliniques et expérimentales récentes sur les troubles cognitifs dans la MRC, et nous en abordons les mécanismes spécifiques potentiels. Parmi les facteurs associés aux atteintes cognitives, l’accumulation des toxines urémiques, comme l’indoxyl sulfate, apparaît comme un facteur de risque spécifique de déclin cognitif. Ces toxines possèdent une toxicité endothéliale pouvant perturber l’endothélium cérébral. La rupture de la barrière hémato-encéphalique (BHE) est un mécanisme impliqué dans plusieurs pathologies neuro-dégénératives et des maladies systémiques à tropisme cérébral. Les résultats de travaux expérimentaux récents dans la MRC indiquent que la rupture de la BHE semble être un mécanisme important des troubles cognitifs au cours de la MRC. Dans les modèles murins de MRC, la perméabilité accrue de la BHE est liée à l’atteinte de la mémoire et à l’activation d’Aryl hydrocarbon Receptor suite à l’accumulation d’indoxyl sufate circulant. Cette rupture de la BHE pourrait également avoir des conséquences néfastes sur la susceptibilité aux accidents vasculaires cérébraux (AVC) et à la neurotoxicité médicamenteuse chez les patients MRC.",Nephrologie & therapeutique,2023,10.1684/ndt.2023.51,https://pubmed.ncbi.nlm.nih.gov/38059844/
PubMed,[The benefits of home visits for patients on home hemodialysis].,"The success of home hemodialysis depends on several criteria. On the one hand, the patient's willingness to be autonomous, his or her degree of understanding, the technical feasibility at home, and the presence of a third party. Secondly, the quality of initial training (which must respect the patient's rhythm) and follow-up at home. This is a true patient-caregiver partnership, based on trust. Home visits are part of this approach, and help maintain the link, as a team at Caen University Hospital can testify.",Revue de l'infirmiere,2023,10.1016/j.revinf.2023.09.008,https://pubmed.ncbi.nlm.nih.gov/37952992/
PubMed,[Pruritus associated with chronic kidney disease in hemodialysis patients: a survey in French nephrologists].,"Chronic kidney disease-associated pruritus (CKD-aP) is common in hemodialysis patients and severely impairs their quality of life, but the practices of nephrologists remain poorly known. The objective of this on-line survey was to describe the management of CKD-aP in French nephrologists affiliated with the French-speaking Society of Nephrology, Dialysis and Transplantation (SFNDT) and involved in hemodialysis. In total, 122 questionnaires were completed and 100 were usable. Nephrologists reported they personally managed a median of 52 patients; they estimated that the CKD-aP prevalence in their hemodialysis patients was a median of 10% (IQR, 6.3-17.2); 6% of nephrologists reported not following any patient with CKD-aP. In case of CKD-aP, the first-intention intervention was the evaluation of phosphocalcic metabolism (53.5%) and verification of dialysis adequacy (52%). For moderate-to-severe CKD-aP, the first-line prescription was topical therapy (71.3%), antihistamine (23.2%) and membrane change (15.9%). Patients were referred to a dermatologist mainly in case of treatment failure (86.9%) or scratching lesions (40.4%). Available treatments were considered ineffective for 50.5% of nephrologists, partially effective for 45.5% and effective for only 4%. These results show that according to the opinion of nephrologists, the pruritus prevalence is low in dialysis patients. This is inconsistent with studies based on systematic patient interviews, thus suggesting that pruritus is a symptom overlooked by nephrologists. In the context of the arrival of a new drug for pruritus, patients should be more questioned about this symptom in order to propose this treatment. Le prurit associé à l’insuffisance rénale chronique (Pa-IRC) est fréquent chez les patients hémodialysés et altère gravement leur qualité de vie, mais les pratiques des néphrologues restent mal connues. L’objectif de cette enquête en ligne était de décrire la prise en charge du Pa-IRC par les néphrologues français hémodialyseurs affiliés à la Société francophone de néphrologie, dialyse et transplantation (SFNDT). Au total, 122 questionnaires ont été remplis et 100 étaient utilisables. Les néphrologues suivaient personnellement 52 patients (médiane). Ils estimaient que la prévalence du Pa-IRC chez ces patients était de 10 % (médiane ; écart interquartile : 6,3-17,2) ; 6 % des néphrologues ont déclaré ne suivre aucun patient atteint de Pa-IRC. En cas de Pa-IRC, l’intervention de première intention était l’évaluation du métabolisme phosphocalcique (53,5 %) et la vérification de la qualité de dialyse (52 %). Pour le Pa-IRC modéré à sévère, la prescription de première intention était un traitement topique (71,3 %), un antihistaminique (23,2 %) et un changement de membrane (15,9 %). Les traitements disponibles étaient considérés comme inefficaces pour 50,5 % des néphrologues, partiellement efficaces pour 45,5 % et efficaces pour seulement 4 %. Ces résultats montrent que selon l’opinion des néphrologues, la prévalence du prurit est faible chez les patients dialysés. Ceci est en contradiction avec les études basées sur des entretiens systématiques avec les patients, suggérant ainsi que le prurit est un symptôme sous-estimé par les néphrologues. Dans le contexte de l’arrivée d’un nouveau médicament pour le prurit, les patients devraient être davantage interrogés sur ce symptôme afin de proposer ce traitement.",Nephrologie & therapeutique,2023,10.1684/ndt.2023.31,https://pubmed.ncbi.nlm.nih.gov/37915193/
PubMed,[The value of preventing constipation in patients treated with peritoneal dialysis: an advanced practice nursing study].,"In 1989, experts developed the Rome criteria classification coupled with the use of the Bristol scale, to objectify the condition of functional constipation.Background Nowadays, little is documented in the literature about transit disorders in patients with End-Stage Chronic Renal Failure treated with peritoneal dialysis, even though this causes non-negligible complications on the patient&#8217;s morbidity, comfort and quality of life. The main objective of our study was to evaluate the prevalence of constipation in CKD patients. We conducted a retrospective multicenter data-driven study. 74 patient records were analyzed. We found a prevalence of constipation of 58&#160;% in patients with CKD. Our results showed that the prevalence of constipation is frequent in patients with CKD. It leads to a significant discomfort for the patient, an additional cost in terms of care and technical procedures and a failure of the peritoneal dialysis technique. Thus, the prevention of constipation in CKD patients would be relevant to limit complications and ensure a better quality of life. En 1989, des experts ont mis au point la classification des critères de Rome couplée à l’utilisation de l’échelle de Bristol, afin d’objectiver l’état de constipation fonctionnelle. Aujourd’hui, la littérature documente peu les troubles du transit des patients en Insuffisance rénale chronique terminale (IRCT) traités par la Dialyse péritonéale (DP), alors même que cela engendre des complications non négligeables sur la morbidité, le confort et la qualité de vie du patient. L’objectif principal de notre étude était d’évaluer la prévalence de la constipation des patients en IRCT. Nous avons réalisé une étude rétrospective multicentrique sur données. 74 dossiers patients ont été analysés. Nous avons mis en évidence une prévalence de la constipation de 58 % chez des patients atteints d’une IRCT. Nos résultats ont démontré que la prévalence de la constipation est fréquente chez les patients atteints d’une IRCT. Elle entraîne un inconfort notable chez le patient, un surcoût au niveau des soins et des actes techniques, et un échec de la technique de dialyse péritonéale. Ainsi, la prévention de la constipation des patients en IRCT serait pertinente pour limiter les complications et leur assurer une meilleure qualité de vie.",Recherche en soins infirmiers,2023,10.3917/rsi.153.0069,https://pubmed.ncbi.nlm.nih.gov/37709668/
PubMed,[Survival of patients with End Stage Kidney Disease].,"On the occasion of the 20th anniversary of the REIN (French Renal Epidemiology and Information Network), a summary work on the contributions of the national French ESKD register was carried out. On the issue of survival of ESKD patients, the following key messages were retained. The annual mortality rates of ESKD patients are relatively stable even though patients are ageing and increasingly have diabetes or obesity. These changes are probably linked to improved practices. Cardiovascular diseases and infections are the main causes of death. The year 2020 was marked by an increase in mortality due to the SARS-CoV-19 infection that was particularly severe in these patients. À l’occasion des 20 ans du REIN (Réseau Epidémiologie et Information en Néphrologie), un travail de synthèse sur les apports du registre a été mené. Sur la question de la survie des patients avec une maladie rénale stade 5, les messages clés suivants ont été retenus. Les taux de mortalité annuels des patients en IRCT sont relativement stables alors même que les patients vieillissent et qu’ils sont de plus en plus souvent porteurs d’un diabète ou d’une obésité. Ces évolutions sont probablement en lien avec une amélioration des pratiques. Les maladies cardiovasculaires et les infections représentent les causes principales de décès. L’année 2020 a été marquée par une augmentation de la mortalité en raison de l’infection à SARS-CoV-19 particulièrement sévère chez ces patients.",Nephrologie & therapeutique,2023,10.1016/S1769-7255(22)00565-X,https://pubmed.ncbi.nlm.nih.gov/37638506/
PubMed,[Incidence of End Stage Kidney Disease and context of dialysis initiation].,"On the occasion of the 20th anniversary of the REIN (French Renal Epidemiology and Information Network), a summary work on the contributions of the national French ESKD register was carried out. On the issue of ESKD incidence, the following key messages were retained. Thanks to several studies conducted using data from the REIN registry, the spatial variations of incidence of stage 5 chronic kidney disease in the replacement stage could be explained, in part, by the health condition of the general population as well as by the socio-economic context and differences in practices. Just like what is observed in other countries, the incidence is stabilising, or even decreasing, especially among people who do not have diabetes. Thanks to the registry having provided an indicator on the initiation of the dialysis, a decrease in the rate of initiation of emergency dialysis (i.e., initiated less than 24 hours after a nephrology evaluation considering a vital risk for the patient) has been observed, resulting from an effort to understand and better anticipate the starting of the replacement. À l’occasion des 20 ans du REIN (Réseau Epidémiologie et Information en Néphrologie), un travail de synthèse sur les apports du registre a été mené. Sur la question de l’incidence de la maladie rénale chronique stade 5, les messages clés suivants ont été retenus. Grâce à plusieurs études menées à partir des données du registre REIN, les variations spatiales d’incidence de la maladie rénale chronique stade 5 au stade de la suppléance ont pu être expliquées, en partie, par l’état de santé de la population générale mais aussi par le contexte socioéconomique et des différences de pratiques. À l’image de ce qui est observé dans d’autres pays, l’incidence est en voie de stabilisation, voire à la baisse, en particulier chez les personnes non diabétiques. Grâce à la mise à disposition par le registre d’un indicateur sur l’initiation de la dialyse, on observe une diminution du taux d’initiation de la dialyse en urgence (c’est-à-dire initiée moins de 24 heures après une évaluation néphrologique considérant un risque vital pour le patient) résultant d’un effort pour comprendre et mieux anticiper le démarrage de la suppléance. L’initiation de la dialyse sur cathéter, autre indicateur de la prise en charge, n’a pour l’instant pas diminué mais avec la mise en place du forfait MRC en octobre 2019 et à distance de la pandémie, la préparation à l’épuration extrarénale devrait être mieux anticipée.",Nephrologie & therapeutique,2023,10.1016/S1769-7255(22)00562-4,https://pubmed.ncbi.nlm.nih.gov/37638503/
PubMed,[The benefits of home visits for peritoneal dialysis patients].,"Peritoneal dialysis is exclusively an extrarenal purification technique performed in the patient's own home. The patient is either autonomous, or assisted by a private nurse or a member of his or her family. The nursing team at the center where the patient is being cared for organizes home visits to meet the patient and his or her family in their living environment. These visits provide an opportunity to review compliance with protocols and maintain the partnership with the patient. The team at the Caen Normandy university center for kidney disease shares its experience in this area of care.",Revue de l'infirmiere,2023,10.1016/j.revinf.2023.07.010,https://pubmed.ncbi.nlm.nih.gov/37633692/
PubMed,"[Chronic kidney disease and nephrological practices in France: lessons from the CKD-REIN cohort, 2013-2023].","Launched in 2013 supported by the Program “Cohorts – Investments for the Future”, the CKD-REIN (Chronic Kidney Disease – Renal Epidemiology and Information Network) study is a prospective cohort that included and followed for 5 years more than 3000 patients with moderate or advanced chronic kidney disease (CKD), from 40 nationally representative nephrology clinics. A large amount of data was collected on CKD and its treatments, patient social characteristics and reported outcomes, and nephrology practices and services. A total of 170,000 blood and urine samples were collected and stored in a central biobank. Coordinated with the CKD outcomes and practice pattern study (CKDopps) and collaborating with the international Network of CKD cohorts (iNETCKD), CKD-REIN contributes to the understanding of CKD and the positioning of France with respect to CKD epidemiology and care in the world. This review highlights major findings from the cohort, and their potential implications for clinical practices and the health system, grouped into the following themes: (1) the complexity of patients with CKD; (2) adherence to clinical guidelines; (3) treatment practices and drug risk; (4) acute on chronic kidney disease; (5) CKD metabolic complications; (6) prediction of kidney failure; (7) sex differences in CKD; (8) patient perspective on CKD; (9) transition to kidney failure and replacement therapy; (10) conservative care. Lancée en 2013 grâce au Programme « Cohortes – Investissements d’Avenir », l’étude CKD-REIN (Chronic Kidney Disease – Renal Epidemiology and Information Network) est une cohorte prospective qui a inclus et suivi pendant cinq ans plus de 3 000 patients avec une maladie rénale chronique (MRC) modérée ou avancée, dans 40 consultations de néphrologie, représentatives nationalement. Un grand nombre de données ont été collectées sur la MRC et ses traitements, les caractéristiques sociales et la santé perçue des patients, les pratiques et l’organisation des services de néphrologie. Une biothèque de 170 000 échantillons de sang et d’urine a été constituée et stockée dans une biobanque centrale. Coordonnée avec l’étude Chronic Kidney Disease outcomes and practice pattern study (CKDopps) et collaborant avec l’International Network of CKD cohorts (iNET-CKD), CKD-REIN contribue à l’avancée des connaissances et au positionnement de la France dans le domaine de l’épidémiologie de la MRC et des pratiques dans le monde. Cette revue fait le point des faits marquants de la cohorte, et de leur implication potentielle pour la clinique et le système de santé, regroupés par thème : (1) la complexité des patients avec une MRC ; (2) l’adhésion aux recommandations cliniques ; (3) les pratiques thérapeutiques et le risque médicamenteux ; (4) l’insuffisance rénale aiguë dans la MRC ; (5) l’évolution des complications métaboliques ; (6) la prédiction de la défaillance rénale ; (7) les différences hommes-femmes ; (8) le point de vue des patients sur la MRC ; (9) la transition vers la défaillance rénale et le traitement de suppléance ; (10) le traitement conservateur.",Nephrologie & therapeutique,2023,10.1684/ndt.2023.35,https://pubmed.ncbi.nlm.nih.gov/37533268/
PubMed,[Nursing support in the decision-making process regarding the choice of renal replacement therapy: A scoping review].,"Chronic kidney disease affects 7 to 10 percent of the French population. Entering the end stage of the disease requires a choice to be made between several options. The aim is to document the nursing practices used to support these patients in choosing their renal replacement therapy and to determine the elements that promote decision-making. This is a scoping review based on the methodology of Peters et al. of JBI. The nursing practices identified focus on empowerment, by intervening in: involvement, providing information, clarifying preferences, supporting deliberation, and assessing needs before, during, and after the decision-making process. The key factors identified are: an equal and trusting relationship, the personalization of the process, and emotional support, all provided by trained professionals. Several concepts shed light on decision support in a complementary and surprisingly paradoxical way: grief, adaptation, empowerment, and uncertainty. This review shows nursing practices centered on helping the patient to take control of their life decisions. This experience causes a serious upheaval in patients’ lives, hence the importance of providing them with support in managing their emotions. L’insuffisance rénale chronique touche 7 à 10 % de la population en France. L’entrée dans le stade terminal de la maladie implique un choix entre plusieurs options. L’objectif est de documenter les pratiques infirmières permettant l’accompagnement de ces patients face à un choix du mode de suppléance et de déterminer les éléments favorisant une prise de décision. Il s’agit d’une revue de portée selon Peters et al. du Johanna Briggs Institut. Les pratiques infirmières identifiées se centrent sur l’empowerment, en intervenant sur l’engagement, l’apport d’informations, la clarification des préférences, l’accompagnement dans la délibération et l’évaluation des besoins avant, pendant et après le processus décisionnel. Les éléments favorisants identifiés sont la relation de confiance égalitaire, la personnalisation du parcours, l’accompagnement émotionnel, ceci, par des professionnels formés. Plusieurs concepts éclairent de façon complémentaire et étonnamment paradoxale l’accompagnement à la décision, comme le deuil, l’adaptation, l’empowerment et l’incertitude. Cette revue montre des pratiques infirmières centrées sur l’acquisition d’un pouvoir d’agir du patient sur sa vie. Cette expérience représente un bouleversement dans la vie des patients et souligne l’importance de l’accompagnement dans la gestion des émotions.",Recherche en soins infirmiers,2023,10.3917/rsi.152.0029,https://pubmed.ncbi.nlm.nih.gov/37438250/
PubMed,[Management of complications of renal failure in hemodialysis patients with IPA].,"The complications of renal failure are likely to have an impact on the quality of life of hemodialysis patients, which is why specific follow-ups are organized by the nephrologist. Advanced practice nurses (APNs) could take care of this alongside physicians. A survey conducted by the Santélys Bourgogne Franche-Comté association shows that professionals are in favor of working with APNs and that follow-up is carried out by medical and paramedical teams without standardized practices. The intervention of an RPN could improve coordination between the different actors.",Soins; la revue de reference infirmiere,2023,10.1016/j.soin.2023.05.008,https://pubmed.ncbi.nlm.nih.gov/37419598/
PubMed,[Comprehensive conservative care for the management of advanced chronic kidney disease].,"Comprehensive “conservative care” is defined as any active therapeutic procedure for the management of stage 5 chronic kidney disease without recourse to dialysis. This therapeutic option is discussed in elderly, frail patients whose anticipated life expectancy is reduced with dialysis. The decision for conservative management primarily relies on an informed choice by the patient and his caregivers. This holistic approach, focused on quality of life, requires a multidisciplinary approach. The goals are to slow the progression of kidney disease, prevent complications, anticipate the risks of decompensation, provide support for the patient and his caregivers to maintain the best possible quality of life at home. This article describes the principles of conservative management, highlights various barriers to this care pathway, and proposes potential solutions. Le « traitement conservateur » se définit comme toute procédure thérapeutique active de prise en charge de la maladie rénale chronique au stade 5, sans recours à la suppléance par dialyse. Cette option thérapeutique est discutée chez des patients âgés, fragiles, dont l’espérance de vie anticipée est réduite en cas de recours à la dialyse. La décision de traitement conservateur repose avant tout sur un choix éclairé du patient et de son entourage. Cette prise en charge holistique, centrée sur la qualité de vie, nécessite une approche multidisciplinaire. Les objectifs sont de ralentir la progression de la maladie rénale, d’en prévenir les complications, d’anticiper les risques de décompensation, d’assurer un soutien au patient et à ses aidants afin de maintenir une qualité de vie la plus acceptable possible à domicile. Cet article décrit les principes du traitement conservateur. Nous mettons en perspective différents freins à ce parcours de soins, ainsi que les solutions qui pourraient être envisagées.",Nephrologie & therapeutique,2023,10.1684/ndt.2023.28,https://pubmed.ncbi.nlm.nih.gov/37381745/
PubMed,[Advances in the management of chronic kidney disease and its complications].,,Nephrologie & therapeutique,2023,10.1684/ndt.2023.30,https://pubmed.ncbi.nlm.nih.gov/37381744/
PubMed,[Not Available].,,Revue medicale suisse,2023,10.53738/REVMED.2023.19.822.738,https://pubmed.ncbi.nlm.nih.gov/37057856/
PubMed,[Chronic kidney disease and growth failure: Efficacy of growth hormone treatment].,"Growth failure is a frequent complication observed in children with chronic kidney disease (CKD) and correlated to increased morbidity and mortality. To achieve a normal growth in children with CKD remains challenging for pediatric nephrologists. Growth failure in the setting of pediatric CKD is multifactorial and related to an impaired sensitivity to growth hormone and to a deficiency of IGF1 (insulin-like growth factor 1). Growth failure management has improved during the last two decades and consists of correcting any nutritional and metabolic abnormalities, of an improvement of dialysis for children on end-stage renal disease, and of an administration of a supraphysiologic dose of recombinant growth hormone to overcome GH insensitivity. This article summarizes the causes, outcomes and assessment tools of growth in children with CKD as well as the management of recombinant growth hormone. Maladie rénale chronique et retard de croissance - Indication et efficacité du traitement par l’hormone de croissance. Le retard de croissance est une des complications les plus fréquentes chez l’enfant présentant une maladie rénale chronique. Il est corrélé à une morbi-mortalité importante, augmentée par les désordres métaboliques qui y sont associés. D’origine multifactorielle, une hypothèse régulièrement avancée est celle d’une résistance à l’hormone de croissance (GH), caractérisée par un déficit en IGF1 (insulin-like growth factor 1). L’obtention d’une croissance staturale satisfaisante reste un défi majeur pour les néphropédiatres. La prise en charge du retard statural comprend différents axes thérapeutiques : une nutrition adaptée aux besoins de l’enfant, une correction des troubles métaboliques avec optimisation de la dialyse, et un traitement par hormone de croissance recombinante à dose supra-physiologique, qui permet de lever la résistance.",Medecine sciences : M/S,2023,10.1051/medsci/2023034,https://pubmed.ncbi.nlm.nih.gov/36943125/
PubMed,[Towards understanding chronic kidney disease].,"Chronic kidney disease (CKD) is a global health problem affecting almost 15% of the population worldwide. After renal injury, there is a nephron loss and remaining nephrons ensure the glomerular filtration rate (GFR) with compensatory hyperplasia and hypertrophy: This is called the nephron reduction. After nephron reduction, renal function will gradually decline and lead to chronic end-stage renal failure. Whatever the initial cause of the renal injury, recent data suggest there are common molecular mechanisms at the origin of CKD progression. Moreover, the renal lesions are very reproducible with glomerulosclerosis, tubular atrophy and partial epithelio-mesenchymal transition, interstitial fibrosis and vascular abnormalities. The physiopathology of CKD progression is unclear but some hypotheses have been described: i) the nephron ""overwork"", supported by recent works showing that the nephron reduction leads to hyperfiltration by the remaining nephrons and the stability of the GFR; ii) the ""podocyte adaptation"" theory, reflected by the importance of the podocytopathy in CKD progression and the crucial role of residual proteinuria in renal lesion development; iii) the activation of EGFR signaling pathways in surgical nephron reduction model and its involvement in CKD progression. Finally, CKD progression remains poorly understood and further studies will be necessary to discover new CKD molecular pathways and to develop new therapeutic insight in CKD management. Aux sources de la compréhensionde la maladie rénale chronique. L’insuffisance rénale chronique est une définition biologique caractérisée par la diminution du débit de filtration glomérulaire. Quelle qu’en soit la cause initiale, son origine est toujours une réduction néphronique, une diminution du nombre d’unités fonctionnelles du rein, appelées néphrons. Après une agression rénale initiale, les néphrons sains restants vont assurer la filtration permettant le maintien d’une fonction rénale normale. Mais, progressivement, ces néphrons vont s’altérer et vont être remplacés par du tissu fibreux. Cette altération du parenchyme va entraîner un ensemble de symptômes biologiques et histologiques réunis sous le terme de maladie rénale chronique : augmentation de la créatininémie, protéinurie, glomérulosclérose et fibrose interstitielle.",Medecine sciences : M/S,2023,10.1051/medsci/2023033,https://pubmed.ncbi.nlm.nih.gov/36943124/
PubMed,[Epidemiology of chronic kidney disease stage V treated in southeastern Algeria: prospective study from 2016 to 2018].,"Chronic kidney disease stage V, by its incidence and its prevalence which are constantly increasing in the world and in Algeria, the morbidity and mortality it generates, the high cost of its treatment, represents a major public health issue. Our objective is to describe the epidemiology of stage V chronic kidney disease treated in south-eastern Algeria. In our regional, multicenter, prospective descriptive study, all patients with stage V chronic kidney disease, residing and treated in south-eastern Algeria between September 1, 2016, and December 31, 2017, were included and followed up until December 31, 2018. Stage V chronic kidney disease is a frequent pathology in the region: 1934 patients were included. It mainly affects young people: the average age of patients was 50.17 ± 16.98 years, with a male predominance of 59.10%. High blood pressure and diabetes are the two main causes. The start of dialysis on a temporary catheter represents 81.5% of cases, the initial management requires emergency dialysis in 91.2% of cases. In total, 97.1% of chronic hemodialysis patients use an arteriove-nous fistula as a permanent vascular access. Our study population is younger than that of developed countries and has fewer comorbidities and disabilities but lower survival and high mortality. The developing national chronic kidney disease stage V registry is becoming an absolute necessity. It will allow to have a better knowledge of its epidemiology and the needs of its care in each region. It can contribute to improving the prevention and management of this disease. La maladie rénale chronique stade V, par son incidence et sa prévalence qui ne cessent d’augmenter en Algérie et dans le monde, la morbi-mortalité qu’elle engendre et le coût élevé de sa prise en charge, représente un enjeu majeur de santé publique. Notre objectif est de décrire l’épidémiologie de cette maladie, traitée dans le Sud-Est algérien. Dans notre étude régionale multicentrique, prospective à visée descriptive, tous les patients atteints de maladie rénale chronique stade V, résidant et traités dans le Sud-Est algérien entre le 1er septembre 2016 et le 31 décembre 2017, ont été inclus et suivis jusqu’au 31 décembre 2018. La maladie rénale chronique stade V est une pathologie fréquente dans la région : 1 934 patients ont été inclus. Elle touche principalement les jeunes : l’âge moyen des patients était de 50,17 ± 16,98 ans, avec une prédominance masculine à 59,10 %. L’hypertension artérielle et le diabète représentent les deux principales causes. Les démarrages de dialyse sur cathéter temporaire représentent 81,5 % des cas, la prise en charge initiale nécessite la dialyse en urgence dans 91,2 % des cas. Un total de 97,1 % des patients hémodialysés chroniques utilisent une fistule artérioveineuse comme abord vasculaire permanent. Notre population d’étude est plus jeune que celle des pays développés et présente un nombre moins important de comorbidités et de handicaps, mais une survie inférieure et une mortalité élevée. Le développement du registre national de la maladie rénale chronique stade V devient une nécessité absolue. Il va permettre une meilleure connaissance de son épidémiologie et des besoins pour sa prise en charge dans chaque région. Il peut contribuer à l’amélioration de la prévention et de la prise en charge de cette maladie.",Nephrologie & therapeutique,2023,10.1684/ndt.2023.4,https://pubmed.ncbi.nlm.nih.gov/36919592/
PubMed,Potentially inappropriate medications and anticholinergic and sedative burden in older community-dwelling patients with advanced chronic kidney disease.,"Regarding older patients, multiple chronic conditions lead to the intake of multiple medications, involving a higher risk of adverse drug events. In older patients with advanced chronic kidney disease, the medication exposure was poorly explored. The aim of this study was to describe the use of potentially inappropriate medications and medications with anticholinergic and sedative properties in older community-dwelling patients with advanced chronic kidney disease. An observational study was conducted in a geriatric day-care unit. All patients aged over 65 years with advanced chronic kidney disease, defined by estimated glomerular filtration rate < 20 mL/min/1.73 m2 or estimated glomerular filtration rate > 20 mL/min/1.73 m2 with rapid progression, and referred by nephrologist for pretransplant comprehensive geriatric assessment, were included in the study. Potentially inappropriate medications were identified using the EU(7)-PIM list, and he anticholinergic and sedative drug exposure was measured using the Drug Burden Index. Overall, 139 patients were included in the study (mean age 74.4 ± 3.3 years, 32.4% females, 61.9% on dialysis). Potentially inappropriate medications were used by 74.1% (103/139) of patients and were mainly represented by proton pump inhibitors, alpha-1-blockers and central antihypertensive drugs. Regarding anticholinergic and / or sedative medications, 79.9% (111/139) of older patients were exposed. In older community-dwelling patients with advanced chronic kidney disease, the prevalence of potentially inappropriate medication exposure and anticholinergic and sedative exposure was high. Interventions focusing on deprescription of these inappropriate medications should be conducted in this specific population. Chez le patient âgé, la polypathologie est souvent associée à la prise de plusieurs médicaments, impliquant un risque élevé d’iatrogénie médicamenteuse. L’exposition médicamenteuse a été peu explorée chez les patients âgés atteints d’insuffisance rénale chronique. L’objectif de cette étude est de décrire l’exposition aux médicaments potentiellement inappropriés et aux médicaments présentant des propriétés anticholinergiques et sédatives chez ces patients. Il s’agit d’une étude observationnelle conduite au sein d’un hôpital de jour gériatrique. Tous les patients âgés de plus de 65 ans avec une maladie rénale chronique avancée, définie par un débit de filtration glomérulaire estimé inférieur à 20 mL/min/1,73 m² ou supérieur à 20 mL/min/1,73 m² avec une progression rapide, et adressés par un néphrologue pour la réalisation d’une évaluation gériatrique standardisée pré-transplantation rénale, ont été inclus dans l’étude. Les médicaments potentiellement inappropriés ont été identifiés à partir de la liste EU(7)-PIM, et l’exposition aux médicaments anticholinergiques et sédatifs a été mesurée à partir du Drug Burden Index. Un total de 139 patients a été inclus dans l’étude (74,4 ± 3,3 ans, 32,4 % de femmes, 61,9 % dialysés). Des médicaments potentiellement inappropriés ont été retrouvés chez 74,1 % (103/139) des patients. Ils étaient principalement représentés par les inhibiteurs de la pompe à protons, les alpha-1-bloquants et les antihypertenseurs centraux. Concernant les médicaments anticholinergiques et/ou sédatifs, 79,9 % (111/139) des patients âgés étaient exposés. L’étude montre que la prévalence de l’exposition aux médicaments potentiellement inappropriés et aux médicaments anticholinergiques et/ou sédatifs est élevée chez les patients âgés atteints de maladie rénale chronique avancée. Des interventions portant sur la déprescription de ces médicaments devraient être menées auprès de cette population spécifique.",Nephrologie & therapeutique,2023,10.1684/ndt.2023.6,https://pubmed.ncbi.nlm.nih.gov/36880102/
PubMed,[EMPA-KIDNEY: empagliflozin in chronic kidney disease].,"The inhibition of the renin-angiotensin system represents the first preventive treatment of the chronic kidney disease (CKD), especially in presence of albuminuria. Recently, sodium-glucose cotransporter type 2 inhibitors (SGLT2i, gliflozins) demonstrated a nephroprotective effect, first in patients with type 2 diabetes at cardiovascular risk, then in diabetic patients with CKD assessed by a reduction of the glomerular filtration rate (GFR) and albuminuria (CREDENCE with canagliflozin), and finally in patients with CKD and albuminuria, with or without diabetes (DAPA-CKD with dapagliflozin). EMPA-KIDNEY study compared the effects of empagliflozin 10 mg/day versus placebo in patients with CKD, with or without diabetes. In comparison with the two previous renal studies, this clinical trial randomised patients with a lower GFR (78 % of patients with GFR inferior to 45 mL/min/1.73 m²) and a lower level of albuminuria (20 % of patients without pathological albuminuria). EMPA-KIDNEY demonstrated a reduction by 28 % (p inferior to 0.001) of the primary composite outcome (progression of CKD or cardiovascular death) and of several renal endpoints, including the shift to terminal CKD (-33 %), independently of the presence of diabetes, and with a tolerance profile comparable to what is already known. EMPA-KIDNEY results reinforce the use of SGLT2is, in general, and of empagliflozin, in particular, in a broader population with CKD and, thus, the indication of this pharmacological class in nephrology in combination with inhibitors of the renin-angiotensin system. L’inhibition du système rénine-angiotensine représente le premier traitement de prévention de la maladie rénale chronique (MRC), en particulier chez les patients avec albuminurie. Récemment, les inhibiteurs des cotransporteurs sodium-glucose de type 2 (iSGLT2, gliflozines) ont démontré une néphroprotection, d’abord chez les patients avec un diabète de type 2 à risque cardiovasculaire, puis chez des patients avec MRC avec diminution du débit de filtration glomérulaire (DFG) et albuminurie (CREDENCE avec la canagliflozine), puis chez des patients avec MRC albuminurique, avec ou sans diabète (DAPA-CKD avec la dapagliflozine). L’étude EMPA-KIDNEY a comparé les effets de l’empagliflozine 10 mg/jour à un placebo chez des patients avec MRC, avec ou sans diabète. Par comparaison aux deux études précédentes, cet essai a recruté des patients avec un DFG plus bas (78 % de patients avec un DFG inf�rieur a 45 mL/min/1,73 m²) et avec un niveau d’albuminurie plus faible (dont 20 % de patients sans albuminurie pathologique). EMPA-KIDNEY a démontré une réduction de 28 % (p inf�rieur a 0,001) du critère primaire composite (progression de la MRC ou mort cardiovasculaire) et de divers critères rénaux secondaires, dont l’évolution vers la MRC terminale (-33 %), indépendamment de la présence d’un diabète, et avec un profil de tolérance de l’empagliflozine comparable à celui déjà connu. EMPA-KIDNEY consolide l’utilisation des iSGLT2, en général, et de l’empagliflozine, en particulier, dans une population plus diversifiée en ce qui concerne la MRC et, donc, l’indication de cette classe pharmacologique en néphrologie en combinaison avec les inhibiteurs du système rénine-angiotensine.e.",Revue medicale de Liege,2023,,https://pubmed.ncbi.nlm.nih.gov/36634063/
PubMed,[Not Available].,"Anemia is a common complication of chronic kidney disease (CKD). The insufficient erythropoietin (EPO) production by the kidneys and iron deficiency are the main causes. Iron supplementation and the administration of recombinant EPO are the main treatment modalities. New iron formulations that can be administered orally, intravenously or directly via the dialysate have recently been developed to improve efficacy and tolerance. Ferric citrate administered orally can effectively corrects anemia in case of iron deficiency and in addition chelate phosphate in the gut lumen. Ferric carboxymaltose allows intravenous administration of larger doses given less frequently. Ferric pyrophosphate citrate administered directly via the dialysate allows the compensation of iron losses during the hemodialysis session. HIF-prolyl-hydroxylase inhibitors are a new therapeutic class of erythropoiesis-stimulating agents. Orally administered, they act by stabilizing the HIF transcription factor involved in the initiation of erythropoietin production by hypoxia. Several clinical studies have recently evaluated these new molecules in comparison with recombinant EPO. In CKD patients not yet on dialysis or undergoing dialysis therapy non-inferiority in correcting anemia has been demonstrated compared with recombinant EPO. The decrease in circulating hepcidin they induce appears greater than that induced by injectable recombinant EPO. Presently available reports on the safety of HIF-prolyl-hydroxylase inhibitors are reassuring but need to be confirmed in longer-term studies of larger size. © 2022 Published by Elsevier Masson SAS on behalf of Société francophone de néphrologie, dialyse et transplantation.",Nephrologie & therapeutique,2022,10.1016/S1769-7255(22)00650-2,https://pubmed.ncbi.nlm.nih.gov/36585122/
PubMed,[Not Available].,"Inhibitors of sodium glucose co-transporter type 2 (iSGLT2) constitute a considerable advance in the management of patients with diabetes, heart failure and with chronic kidney disease (CKD). Randomized controlled studies have shown a significant reduction of cardiovascular risk in diabetic type 2 and/or heart failure with reduced ejection fraction patients. These studies observed a risk reduction of worsening nephropathy, leading to randomized controlled studies in CKD patients : CREDENCE, DAPA-CKD and EMPA-KIDNEY. iSGLT2 are associated with a slower progression toward end-stage kidney disease, a lower slope of GFR and a lower rate of albuminuria. In CKD patients with proteinuria either diabetic or not, the DAPA-CKD and the EMPA-KIDNEY studies have demonstrated a nephroprotective effect. This effect has not been found for patients without proteinuria. For the other nephropathies, further studies are required to confirm results obtained in patients without type 2 diabetes and macroalbuminuria. Therefore, the indication of iSGLT2, with appropriate dose of RAS inhibitor, seems undeniable to an optimal nephroprotection in CKD patients with type 2 diabetes and/or albuminuria and/or heart failure. They must be prescribed in addition to conventional nephroprotective and cardioprotective treatments and care. Side effects are limited. However, special education and monitoring concerning risks of genital infection and euglycemic ketoacidosis (diabetic patients) must be taken in mind. The therapeutic arsenal for CKD patients is expanding, leading to consider a personalized care according to the underlying nephropathy. © 2022 Published by Elsevier Masson SAS on behalf of Société francophone de néphrologie, dialyse et transplantation.",Nephrologie & therapeutique,2022,10.1016/S1769-7255(22)00649-6,https://pubmed.ncbi.nlm.nih.gov/36585121/
PubMed,[Not Available].,"Chronic Kidney Disease associated Pruritus (CKD-aP) is a well-established and frequent complication observed in patient with CKD, especially in dialysis patients. However, the management of CKD-aP remains a challenge as the pathophysiology and research studies are too small. Finally, there are a few proposed treatment options with significant clinical benefits. This general review will summarize all the available treatments for the CKD-aP and will highlight the clinical efficacy and limits of the current drugs. Notably, we will focus on the implication of the opioid receptor in the pathophysiology of the CKD-aP and the recently Kappa opioid receptor agonist. © 2022 Published by Elsevier Masson SAS on behalf of Société francophone de néphrologie, dialyse et transplantation.",Nephrologie & therapeutique,2022,10.1016/S1769-7255(22)00648-4,https://pubmed.ncbi.nlm.nih.gov/36585120/
PubMed,[Management of iron deficiency in chronic kidney disease: Review and proposed algorithm].,"Iron deficiency is very common in chronic kidney disease, even before the dialysis stage. It is an independent factor of morbidity and mortality in patients with non-dialysis chronic kidney disease. During chronic kidney disease, iron deficiency is defined by a transferrin saturation <20% and/or a serum ferritin <100 μg/L. In France, about half of non-dialysis chronic kidney disease patients have absolute iron deficiency (transferrin saturation <20% and serum ferritin <100 μg/L) and/or functional iron deficiency (transferrin saturation <20% and serum ferritin >100 μg/L). Despite this, iron deficiency is usually not investigated. In fact, more than 60% of nephrologists do not assess iron status at least once a year. In addition, iron deficiency is rarely treated: only 12% of patients are prescribed oral or intravenous iron. Early detection and treatment are fundamental and should be systematic. In order to help improve the management of iron deficiency among non-dialysis chronic kidney disease patients, we propose an algorithm that takes into account current recommendations and the most recent data from the literature. Initial blood test requires the measurement of hemoglobin concentration, transferrin saturation and serum ferritin. A transferrin saturation <20% establishes the diagnosis of iron deficiency and the serum ferritin level points towards an absolute or functional deficiency. The combination of both values makes it possible to adapt the treatment, particularly in an inflammatory context where oral iron is not effective.",Nephrologie & therapeutique,2022,10.1016/j.nephro.2022.10.003,https://pubmed.ncbi.nlm.nih.gov/36435741/
PubMed,[Nephrologist-IPA collaboration for better patient management].,"Chronic kidney disease, the extreme consequence of which is dialysis or transplantation, requires a highly structured care pathway, marked by precise care and treatment recommendations. Given the aging of the population, the increase in the number of patients is inevitable. Synergy between nephrologists and advanced practice nurses allows the implementation of organization protocols in fields of competence including consultations and prescriptions.",Soins; la revue de reference infirmiere,2022,10.1016/j.soin.2022.05.028,https://pubmed.ncbi.nlm.nih.gov/36127019/
PubMed,Glomerular Filtration Rate Abnormalities in Children With Type 1 Diabetes.,"Type 1 diabetes (T1D) increases the risk of chronic kidney disease (CKD) development. The primary objective of this study was to assess the prevalence of abnormalities in estimated glomerular filtration rate (eGFR) in children with T1D. As a secondary objective, we sought to explore the relationship between clinical characteristics and abnormalities in eGFR. This cross-sectional study involved children ≤18 years of age with T1D followed in the diabetes clinic at a pediatric tertiary care centre. Data were collected from health records between 2016 and 2020. Using the Bedside Schwartz, Chronic Kidney Disease in Children Under 25 (CKiD U25) and European Kidney Function Consortium (EKFC) equations, eGFR was categorized as CKD (<60 mL/min/1.73 m Of the 420 participants, 225 were male (54%); the median age at diagnosis and duration of T1D were 6.1 and 4.8 years, respectively. The proportion of participants with mildly decreased eGFR was similar regardless of eGFR equation, with 11% to 14% of participants with an eGFR <90 mL/min/1.73 m A notable proportion of children with T1D demonstrates eGFR abnormalities early in their T1D course. This finding along with evidence of lower eGFR in adolescence is concerning for long-term risk of CKD and warrants systematic serum creatinine monitoring at diagnosis and regular intervals thereafter in children with T1D.",Canadian journal of diabetes,2022,10.1016/j.jcjd.2022.01.007,https://pubmed.ncbi.nlm.nih.gov/35752567/
PubMed,AWAREness of Diagnosis and Treatment of Chronic Kidney Disease in Adults With Type 2 Diabetes (AWARE-CKD in T2D).,"Diabetes remains the leading contributor to the development of chronic kidney disease (CKD) and end-stage kidney disease, emphasizing the urgency of identifying barriers to early diagnosis and intervention. The primary objective of this study was to describe the awareness, values and preferences of physicians and patients with respect to managing CKD among patients with type 2 diabetes (T2D). A cross-sectional survey was conducted among physicians and adult patients with T2D and CKD based on estimated glomerular filtration rate and urine albumin-to-creatinine ratio (uACR) measured within 1 year. Physicians were recruited from email networks across Canada, excluding Alberta, and patients were recruited from LMC Diabetes and Endocrinology clinics in Ontario and Quebec. Two separate surveys were developed by a steering committee. Survey responses from 160 physicians (60 general practitioners, 50 endocrinologists and 50 nephrologists) and 169 patients were analyzed descriptively. Gaps in physician care included insufficient use of uACR screening, limited knowledge or use of Kidney Disease Improving Global Outcomes (KDIGO) and KidneyWise resources and lower than expected prescription of recommended therapies. The patient data showed 51.5% of patients were unaware of a CKD diagnosis, and 75.6% of patients who received a prior CKD diagnosis would have preferred an earlier diagnosis. The results highlight several opportunities for improving CKD in T2D management. More education and clarity are needed for physicians interpreting uACR levels that should prompt a referral to a nephrologist, and additional understanding of kidney risk progression is vital for patients.",Canadian journal of diabetes,2022,10.1016/j.jcjd.2022.01.008,https://pubmed.ncbi.nlm.nih.gov/35739044/
